DE60210139D1 - Pharmazeutische zusammensetzungen enthaltend tegaserod - Google Patents

Pharmazeutische zusammensetzungen enthaltend tegaserod

Info

Publication number
DE60210139D1
DE60210139D1 DE60210139T DE60210139T DE60210139D1 DE 60210139 D1 DE60210139 D1 DE 60210139D1 DE 60210139 T DE60210139 T DE 60210139T DE 60210139 T DE60210139 T DE 60210139T DE 60210139 D1 DE60210139 D1 DE 60210139D1
Authority
DE
Germany
Prior art keywords
tegaserod
pharmaceutical compositions
compositions contain
contain
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210139T
Other languages
English (en)
Other versions
DE60210139T2 (de
Inventor
Jerome Aubert
Christian Vitzling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60210139D1 publication Critical patent/DE60210139D1/de
Publication of DE60210139T2 publication Critical patent/DE60210139T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60210139T 2001-12-21 2002-12-20 Pharmazeutische zusammensetzungen enthaltend tegaserod Expired - Lifetime DE60210139T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403339 2001-12-21
EP01403339A EP1321142A1 (de) 2001-12-21 2001-12-21 Feste orale Zubereitung mit Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE60210139D1 true DE60210139D1 (de) 2006-05-11
DE60210139T2 DE60210139T2 (de) 2006-08-17

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210139T Expired - Lifetime DE60210139T2 (de) 2001-12-21 2002-12-20 Pharmazeutische zusammensetzungen enthaltend tegaserod

Country Status (31)

Country Link
US (2) US20050106236A1 (de)
EP (2) EP1321142A1 (de)
JP (1) JP4718776B2 (de)
KR (1) KR100980144B1 (de)
CN (1) CN100464749C (de)
AR (1) AR037937A1 (de)
AT (1) ATE320807T1 (de)
AU (1) AU2002361198B2 (de)
BR (1) BR0215148A (de)
CA (1) CA2470668C (de)
CO (1) CO5640102A2 (de)
CY (1) CY1105559T1 (de)
DE (1) DE60210139T2 (de)
DK (1) DK1458377T3 (de)
EC (1) ECSP105163A (de)
EG (1) EG24194A (de)
ES (1) ES2258171T3 (de)
HU (1) HU226589B1 (de)
IL (2) IL162451A0 (de)
MX (1) MXPA04006157A (de)
MY (1) MY139546A (de)
NO (1) NO20042779L (de)
NZ (1) NZ533585A (de)
PE (1) PE20030872A1 (de)
PL (1) PL369509A1 (de)
PT (1) PT1458377E (de)
RU (1) RU2322978C2 (de)
SI (1) SI1458377T1 (de)
TW (1) TWI260221B (de)
WO (1) WO2003053432A1 (de)
ZA (1) ZA200404467B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228179B1 (en) * 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
SG146608A1 (en) 2003-09-12 2008-10-30 Amgen Inc Dw Us Rapid dissolution formulation of a calcium receptor-active compound
EP1594493A2 (de) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphe formen von tegaserod-base und ihre salze
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2384318T3 (pl) 2008-12-31 2018-04-30 Ardelyx, Inc. Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego
EP2887964B1 (de) 2012-08-21 2019-07-03 Ardelyx, Inc. Verbindungen und verfahren zur hemmung von nhe-vermitteltem antiport bei der behandlung von erkrankungen im zusammenhang mit flüssigkeitsretention oder salzüberlastung und erkrankungen des gastrointestinaltraktes
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
RS58969B1 (sr) 2013-04-12 2019-08-30 Ardelyx Inc Jedinjenja koja se vezuju za nhe3 i postupci za inhibiranje transporta fosfata
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
HU228179B1 (en) * 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.

Also Published As

Publication number Publication date
DK1458377T3 (da) 2006-06-12
KR20040066922A (ko) 2004-07-27
EP1458377A1 (de) 2004-09-22
CO5640102A2 (es) 2006-05-31
ES2258171T3 (es) 2006-08-16
IL162451A0 (en) 2005-11-20
NO20042779L (no) 2004-09-17
IL162451A (en) 2009-02-11
JP4718776B2 (ja) 2011-07-06
TWI260221B (en) 2006-08-21
CA2470668A1 (en) 2003-07-03
BR0215148A (pt) 2004-10-19
RU2004122631A (ru) 2005-08-10
RU2322978C2 (ru) 2008-04-27
TW200410684A (en) 2004-07-01
US20050106236A1 (en) 2005-05-19
MY139546A (en) 2009-10-30
DE60210139T2 (de) 2006-08-17
EP1458377B1 (de) 2006-03-22
PL369509A1 (en) 2005-04-18
HUP0402492A2 (hu) 2005-07-28
AU2002361198A1 (en) 2003-07-09
AR037937A1 (es) 2004-12-22
AU2002361198B2 (en) 2006-06-08
NZ533585A (en) 2006-04-28
PT1458377E (pt) 2006-07-31
CN100464749C (zh) 2009-03-04
US20090104263A1 (en) 2009-04-23
PE20030872A1 (es) 2003-11-24
ATE320807T1 (de) 2006-04-15
CA2470668C (en) 2011-07-05
HUP0402492A3 (en) 2008-04-28
ZA200404467B (en) 2006-05-31
EP1321142A1 (de) 2003-06-25
MXPA04006157A (es) 2004-10-27
CN1606438A (zh) 2005-04-13
CY1105559T1 (el) 2010-07-28
EG24194A (en) 2008-10-14
JP2005516946A (ja) 2005-06-09
SI1458377T1 (sl) 2006-08-31
KR100980144B1 (ko) 2010-09-03
ECSP105163A (es) 2010-07-30
HU226589B1 (en) 2009-04-28
WO2003053432A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
DE60210139D1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
NO20033556L (no) Farmasöytiske formuleringer
NO20033384L (no) Farmasoytisk formulering
FI20011478A (fi) Farmaseuttinen koostumus
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
PT1501534E (pt) Formulacoes farmaceuticas
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ATE468324T1 (de) Pharmazeutische zusammensetzung
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
FI20022128A (fi) Farmaseuttinen koostumus
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20044164L (no) Farmasoytiske sammensetninger
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0102572D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN